Patents by Inventor Gianluca Carlesso
Gianluca Carlesso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220251204Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: December 14, 2021Publication date: August 11, 2022Inventors: Srinath KASTURIRANGAN, Changshou GAO, Godfrey RAINEY, Michelle MORROW, Claire Louise DOBSON, Stacey DRABIC, Darren SCHOFIELD, Gianluca CARLESSO, Kristen POLLIZZI, Yariv MAZOR, Michael OBERST, Scott A. HAMMOND, Brian LOBO, Prakash MANIKWAR, Jonathan SEAMAN, Simon DOVEDI, Ronald HERBST
-
Patent number: 11279759Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: September 13, 2019Date of Patent: March 22, 2022Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Publication number: 20200216541Abstract: Herein described are liquid formulations of antibodies and biologically active fragments thereof that specifically bind to a human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.Type: ApplicationFiled: December 12, 2019Publication date: July 9, 2020Inventors: Hasige Sathish, Ambarish Shah, Gianluca Carlesso, Tracy Delaney
-
Publication number: 20200199567Abstract: The disclosure provides methods for the selection and isolation of T cells expressing programmed cell death 1 (PD-1) and for selecting a PD-1 expression level of the isolated PD-1 expressing T cells. The disclosure also provides methods of large scale expansion of selected and isolated PD-1 expressing T cells, as well as methods for treating a subject comprising administering selected and isolated PD-1 expressing T cells to the subject.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Inventors: SHINO HANABUCHI, JOHN MUMM, DANIEL J. FREEMAN, JINLIN JIANG, SOMEET NARANG, RONALD HERBST, DANIELLE TOWNSLEY, GIANLUCA CARLESSO, TAEIL KIM
-
Publication number: 20200172622Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: September 13, 2019Publication date: June 4, 2020Inventors: SRINATH KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN, SIMON DOVEDI, RONALD HERBST
-
Patent number: 10457732Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: May 5, 2017Date of Patent: October 29, 2019Assignee: MEDIMMUNE, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst
-
Publication number: 20180022807Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: ApplicationFiled: May 5, 2017Publication date: January 25, 2018Applicant: MEDIMMUNE, LLCInventors: Srinath KASTURIRANGAN, CHANGSHOU GAO, GODFREY RAINEY, MICHELLE MORROW, CLAIRE LOUISE DOBSON, STACEY DRABIC, DARREN SCHOFIELD, GIANLUCA CARLESSO, KRISTEN POLLIZZI, YARIV MAZOR, MICHAEL OBERST, SCOTT A. HAMMOND, BRIAN LOBO, PRAKASH MANIKWAR, JONATHAN SEAMAN
-
Publication number: 20170174766Abstract: Herein described as liquid formulations of antibodies and biologically active fragments thereof that specifically bind to human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.Type: ApplicationFiled: December 12, 2016Publication date: June 22, 2017Inventors: Hasige Sathish, Ambarish Shah, Gianluca Carlesso, Tracy Delaney
-
Patent number: 9193789Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonization) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.Type: GrantFiled: September 6, 2012Date of Patent: November 24, 2015Assignee: MedImmune, LLCInventors: Anthony Coyle, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
-
Publication number: 20130142783Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.Type: ApplicationFiled: September 6, 2012Publication date: June 6, 2013Applicant: MEDIMMUNE, LLCInventors: Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
-
Publication number: 20110293605Abstract: Herein described are liquid formulations of antibodies and biologically active fragments thereof that specifically bind to a human ICOS polypeptide, exhibit increased in vivo ADCC activity and undergo reversible self-association in solution.Type: ApplicationFiled: November 12, 2009Publication date: December 1, 2011Inventors: Hasige Sathish, Ambarish Shah, Gianluca Carlesso, Tracy Delaney
-
Publication number: 20110243929Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.Type: ApplicationFiled: December 17, 2010Publication date: October 6, 2011Applicant: Medlmmune, LLCInventors: Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
-
Publication number: 20080279851Abstract: The present invention provides anti-human ICOS antibodies with increased effector function. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human ICOS antigen and that may mediate ADCC, CDC, and/or antibody-dependent phagocytosis (opsonisation) for the treatment and prevention of T cell-mediated diseases and disorders, such as, but not limited to, chronic infection, autoimmune disease or disorder, inflammatory disease or disorder, graft-versus-host disease (GVHD), transplant rejection, and T cell proliferative disorder.Type: ApplicationFiled: May 7, 2008Publication date: November 13, 2008Applicant: Medlmmune, LLCInventors: Anthony COYLE, Yihong Yao, Bahija Jallal, Gianluca Carlesso, Michael Bowen
-
Publication number: 20050266090Abstract: The present invention provides biocompatible, low molecular weight nanoparticulate formulations that are designed to retain and deliver therapeutics over an extended time course. The therapeutic may be conjugated or adsorbed to the periphery of the corona or conjugated to a core polymer. The nanoparticles comprise targeting ligands also conjugated or adsorbed to the periphery of the corona and/or a contrast agent in the core of the nanoparticle. As such, methods of selective targeting and/or methods of noninvasive imaging using bioluminescence and/or magnetic resonance imaging. Also provided are methods of delivering to and, optionally, imaging of a cell or tissue. Further provided are methods of producing the nanoparticles in batch or continuous mode via simple mixing or laminar flow.Type: ApplicationFiled: May 10, 2005Publication date: December 1, 2005Inventors: Ales Prokop, Jeffrey Davidson, Gianluca Carlesso, David Roberts
-
Publication number: 20050008572Abstract: The present invention provides a series of biocompatible, nanoparticulate formulations that are designed to retain and deliver peptides such as anti-angiogenic factors over an extended time course. The nanoparticles can be targeted to a cell or tissue by targeting ligands crosslinked or conjugated to the corona of the nanoparticles. In addition to selective targeting, the nanoparticles also may perform noninvasive imaging using bioluminescence and/or magnetic resonance imaging via a contrast agent in the core of the nanoparticle. Also provided are methods of delivering to and, optionally, imaging of a cell or tissue. Furthermore, methods of producing the nanoparticles in batch or continous mode via simple mixing or micromixing.Type: ApplicationFiled: April 28, 2004Publication date: January 13, 2005Inventors: Ales Prokop, Jeffrey Davidson, Gianluca Carlesso, David Roberts
-
Publication number: 20040136961Abstract: The present invention provides compositions comprising a water-based core solution and a water-based corona solution surrounding the core solution. The compositions comprise polyanionic polymers and salts and polycationic polymers and cations and is useful for adenoviral delivery of a gene or delivery of another drug. The compositions may be nanoparticulate, microcapsular or form a polymeric sheet. Also provided are methods of use for the compositions.Type: ApplicationFiled: June 30, 2003Publication date: July 15, 2004Inventors: Ales Prokop, Jeffrey M. Davidson, Gianluca Carlesso, Derya Unutmaz
-
Patent number: RE49908Abstract: The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.Type: GrantFiled: June 30, 2021Date of Patent: April 9, 2024Assignee: MedImmune, LLCInventors: Srinath Kasturirangan, Changshou Gao, Godfrey Rainey, Michelle Morrow, Claire Louise Dobson, Stacey Drabic, Darren Schofield, Gianluca Carlesso, Kristen Pollizzi, Yariv Mazor, Michael Oberst, Scott A. Hammond, Brian Lobo, Prakash Manikwar, Jonathan Seaman, Simon Dovedi, Ronald Herbst